search
Back to results

The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.

Primary Purpose

Chronic Postsurgical Pain

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
S-ketamine and pregabalin
Normal saline and placebo capsule
Sponsored by
Beijing Tiantan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Postsurgical Pain focused on measuring Esketamine, Pregabalin, Craniotomy, Chronic Postsurgical Pain

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults, age ≥18 years, male or female
  • American Society of Anaesthesiology (ASA) status I-III
  • Patients undergoing elective craniotomy

Exclusion Criteria:

  • Patients unable to complete scale assessment
  • Pregnant or lactating women
  • Patients with preoperative chronic pain syndrome
  • Patients with previous craniotomy history
  • Patients with a history of mental illness who are receiving medication
  • Patients with liver and kidney dysfunction
  • Patients have taken pain medication within two weeks
  • Patients with history of adverse reactions to pregabalin, ketamine and esticketamine
  • Patients with history of drug abuse;
  • BMI>35.0 kg · m - 2.

Sites / Locations

  • Beijing Tiantan Hospital, Capital Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

S-ketamine and pregabalin

Normal saline and placebo capsule

Arm Description

Drug: S-ketamine and pregabalin Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14) Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h

Drug: Normal saline and placebo capsule Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours

Outcomes

Primary Outcome Measures

Proportion of craniotomy patients with NRS score greater than one 3 months after surgery

Secondary Outcome Measures

Full Information

First Posted
December 7, 2021
Last Updated
May 8, 2022
Sponsor
Beijing Tiantan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05160493
Brief Title
The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.
Official Title
The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 20, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tiantan Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Chronic postsurgical pain (CPSP), which is one of the most common and serious long term complication of surgery,occurs in approximately 10% of patients after a surgical procedure. Craniotomy was previously considered to have less chronic pain than other surgical procedures. Contrarily, studies have reported incidences of chronic headache varies for type of craniotomy, ranging from 23% to 34% at three months and 12% to 16% at one year after surgery. In addition,CPSP is associated with adverse events, including postoperative morbidity, increased health-care costs, significant impaired on quality of life, prolonged opioid use. Optimising perioperative pain management should reduce the incidence of CPSP; The non-opioid analgesics, such as ketamine and pregabalin, have also been used as components of multimodal anesthetic protocols. Postoperative pain scores and opioid use are significantly reduced in thoracotomy surgical patients given ketamine and pregabalin compared to control groups.however, there is currently a lack of evidence regarding which therapeutic options are most effective in reducing the incidence of chronic post-craniotomy headache. The investigators hypothesis is that sketamine combined with pregabalin reduces significantly chronic postoperative pain after craniotomy and improves patient outcome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Postsurgical Pain
Keywords
Esketamine, Pregabalin, Craniotomy, Chronic Postsurgical Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation
Randomized
Enrollment
246 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
S-ketamine and pregabalin
Arm Type
Experimental
Arm Description
Drug: S-ketamine and pregabalin Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14) Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Arm Title
Normal saline and placebo capsule
Arm Type
Placebo Comparator
Arm Description
Drug: Normal saline and placebo capsule Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours
Intervention Type
Drug
Intervention Name(s)
S-ketamine and pregabalin
Intervention Description
S-ketamine and pregabalin Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14) Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Intervention Type
Drug
Intervention Name(s)
Normal saline and placebo capsule
Intervention Description
Normal saline and placebo capsule
Primary Outcome Measure Information:
Title
Proportion of craniotomy patients with NRS score greater than one 3 months after surgery
Time Frame
3 months after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults, age ≥18 years, male or female American Society of Anaesthesiology (ASA) status I-III Patients undergoing elective craniotomy Exclusion Criteria: Patients unable to complete scale assessment Pregnant or lactating women Patients with preoperative chronic pain syndrome Patients with previous craniotomy history Patients with a history of mental illness who are receiving medication Patients with liver and kidney dysfunction Patients have taken pain medication within two weeks Patients with history of adverse reactions to pregabalin, ketamine and esticketamine Patients with history of drug abuse; BMI>35.0 kg · m - 2.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ruquan Han, M.D., Ph D.
Phone
8610-59976660
Email
ruquan.han@ccmu.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ruquan Han, M.D., Ph D.
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Tiantan Hospital, Capital Medical University
City
Fengtai Dist.
State/Province
Beijing
ZIP/Postal Code
100070
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruquan Han, M.D., Ph.D
Phone
8610-59976660
Email
ruquan.han@gmail.com
First Name & Middle Initial & Last Name & Degree
Ruquan Han, M.D., Ph.D

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.

We'll reach out to this number within 24 hrs